Medical/Pharmaceuticals

BioDlink Named "Emerging CDMO of the Year" at the 2026 Asia-Pacific Biopharma Excellence Awards

* BioDlink has been named "Emerging CDMO of the Year" for its innovation in complex biologics and ADC development. * The award recognizes its proprietary technology platforms, scalable manufacturing, and a proven quality system with over 100 audits completed. SUZHOU,China, March 13, 2026 /PRN...

2026-03-13 21:00 7546

Unixell Biotech receives IND clearance by FDA for its Allogeneic iPSC-Derived cell therapy, UX-GIP001, for focal Epilepsy

SHANGHAI, March 13, 2026 /PRNewswire/ -- On March 12, Unixell Biotech achieved a significant milestone as UX-GIP001, its iPSC-derived allogeneic cell therapy targeting focal epilepsy, secured Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA). This breakthro...

2026-03-13 20:06 4399

POMDOCTOR LIMITED Announces Strategic Upgrade, Focusing on "AI + Medical-Grade Smart Wearables" to Build a New Ecosystem for Full-Cycle Chronic Disease Management

GUANGZHOU, China, March 13, 2026 /PRNewswire/ -- Pomdoctor Limited ("Pomdoctor" or the "Company") (NASDAQ: POM), a leading online medical services platform for chronic diseases inChina, today announced a strategic upgrade centered on the core track of "artificial intelligence ("AI") + medical-gra...

2026-03-13 20:00 6619

Aphranel Named to Forbes China Beauty 100 List

SHANGHAI, March 12, 2026 /PRNewswire/ -- Aphranel, a China-origin regenerative medical aesthetics brand under the companySHANGHAI MOYANG BIOTECHNOLOGY, has been named to the Third Forbes China Beauty 100 list, published byForbes China, which recognizes brands in China's beauty and medical aesthet...

2026-03-13 11:23 4673

WuXi Biologics Wins Multiple Asia-Pacific Biopharma Excellence Awards for Leadership in Bioprocessing, Manufacturing Excellence, and Digital Innovation

SINGAPORE, March 12, 2026 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), announced that it has won six prestigious awards and two individual leadership awards at the 2026 Asia-Pacific Biopharma Excelle...

2026-03-13 11:09 5027

PRISM BioLab and Receptor.AI Announce Drug Discovery Collaboration Agreement

— Advancing the Discovery of Novel Therapies and Building an Integrated Drug Discovery Platform by Combining PPI Science with AI — TOKYO, March 12, 2026 /PRNewswire/ -- PRISM BioLab Co., Ltd. ("PRISM") and Receptor.AI Inc. today announced that they have entered into a drug discovery collaboratio...

2026-03-13 08:00 3593

ImmunoForge to Conduct Strategic Partnering at Bio-Europe Spring 2026

* Conducting global licensing partnering of LMT15, a proprietary BBB Shuttle platform * Also discussing global out-licensing of Phase 2 stage new drugs PF1801 and PF1804 SEOUL, South Korea, March 12, 2026 /PRNewswire/ -- ImmunoForge Co., Ltd. , a biopharmaceutical company developing treatments...

2026-03-12 16:58 5059

Ulike Announces Official Partnership with the PCOS Awareness Association (PCOSAA)

NEW YORK, March 11, 2026 /PRNewswire/ -- Millions of women worldwide live with Polycystic Ovary Syndrome (PCOS), a complex hormonal condition that remains widely underdiagnosed, stigmatized, and misunderstood. Beyond its medical implications, PCOS often affects mental health, self-esteem, and dai...

2026-03-11 21:00 4356

GC Biopharma Publishes a Comprehensive Review Paper Summarizing 30 Years of Accumulated Data on Its Proprietary Varicella Vaccine Strain, 'MAV/06'

* Demonstrates effectiveness comparable to the global standard Oka strain vaccine YONGIN, South Korea, March 11, 2026 /PRNewswire/ -- GC Biopharma(006280.KS), a leading provider of biopharmaceutical products inSouth Korea, announced today that a review paper comprehensively analyzing the safety...

2026-03-11 13:50 5991

Tsingke Biotech and iGeneTech Forge Strategic Partnership to Lead Synthetic Biology Advancements

BEIJING, March 10, 2026 /PRNewswire/ -- Beijing Tsingke Biotech Co., Ltd. (" Tsingke Biotech ") and iGeneTech Bioscience Co., Ltd. ("iGeneTech") have announced a strategic partnership aimed at advancing the field of synthetic biology. This collaboration brings together th...

2026-03-10 22:13 6496

Registrational Phase III AMPLIFY trial: Target number of participants achieved

SYDNEY, March 10, 2026 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity" or "Company"), a clinical-stage radiopharmaceutical company with a mission to develop next-generation products that improve treatment outcomes for patients with cancer, is pleased to announce that the Phase III A...

2026-03-10 21:02 7346

The 0.05 EU/mg Breakthrough: How Sino Biological ProPure™ Is Redefining the Ultra-Low Endotoxin Standard

HOUSTON, March 10, 2026 /PRNewswire/ -- While exotoxins dominate discussions of bacterial infections, endotoxins—cell wall components released upon bacterial death—are equally dangerous. These endotoxins trigger hyperinflammatory responses that spiral into endotoxemia, in which bloodstream endoto...

2026-03-10 15:22 4623

IgHM - A New Breakthrough in Immunonutrition

HO CHI MINH CITY, Vietnam, March 9, 2026 /PRNewswire/ -- With an orientated development based on scientific nutrition, VitaDairy (Vietnam) has officially introduced its new ColosBaby Lactoferrin - a nutritional formula, which is utilized with many superior nutrients such as a super-immune complex...

2026-03-09 19:13 4129

Harbour BioMed and Kelun-Biotech Announce NMPA Approval of IND Application for HBM7575/SKB575 for the Treatment of Atopic Dermatitis

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 9, 2026 /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, and Kelun-Biotech (6990.HK) today announced ...

2026-03-09 16:32 6492

Leads Biolabs' Opamtistomig (LBL-024) Enrolls First ESCC Patient, Exploring Dual PD-L1/4-1BB Mechanism for Superior Survival Benefits in China's High-Incidence Cancer

NANJING, China, March 9, 2026 /PRNewswire/ -- Nanjing Leads Biolabs Co., Ltd. ("Leads Biolabs" or the "Company," Stock Code: 9887.HK)announced on March 6, 2026 that the first patient has been successfully dosed in a Phase Ⅱ clinical study evaluating Opamtistomig (LBL-024), the company's core inve...

2026-03-09 14:28 6913

Global Times: Understanding 'people' at the heart of Healthy China

"Building a Healthy China by 2035 is a strategic decision made by the Communist Party ofChina (CPC) Central Committee." BEIJING, March 7, 2026 /PRNewswire/ -- On Friday afternoon, Xi Jinping, General Secretary of the CPC Central Committee, visited the members of the Chinese Peasants and Workers ...

2026-03-07 18:47 4944

CARsgen Therapeutics Announces 2025 Annual Results

SHANGHAI, March 6, 2026 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on developing innovative CAR T-cell therapies, has announced its 2025 Annual Results. Business Highlights * Cash and cash equivalents were around RMB1,123 million as of Decemb...

2026-03-06 20:03 11178

Insilico and TaiGen Achieve Milestone in Collaboration: Out-Licensed CKD Anemia Candidate ISM4808 Completes first human enrollment and dosing in Phase I clinical trial

CAMBRIDGE, Mass., March 5, 2026 /PRNewswire/ -- Insilico Medicine (Insilico Medicine, HKEX: 03696), a clinical-stage biotechnology company powered by generative artificial intelligence (AI), announced that ISM4808, an AI-driven PHD inhibitor for chronic kidney disease (CKD)-related anemia previou...

2026-03-06 18:53 6814

Datasea Accelerates Global Commercialization of Acoustic + AI Health Care Robots, Expanding Scalable Applications in China and International Markets

Initial Technical Service Revenue Achieved as the Company Advances Global Deployment and Chain Expansion with Strategic Partner BEIJING, March 5, 2026 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), a technology company specializing in acoustic high-tech innovation and ...

2026-03-05 22:30 5095

Cerecin Announces TEDx Talk by CEO Dr. Charles Stacey is Now Available Online

Titled "The Potential of Fasting and Diet in the Future of Medicine" Highlighting the Potential of Ketones - from Fasting, the Ketogenic diet and Pharmaceuticals - to Address Neurological Disease and Improve Brain Health DENVER, Colo., March 5, 2026 /PRNewswire/ -- Cerecin Inc., a clinical-stage ...

2026-03-05 22:28 4374
1 ... 21222324252627 ... 261

Week's Top Stories